Alteogen

(주)알테오젠 · KOSDAQ · 196170 · Industry: Research and experimental development on medical sciences and pharmacy

Key metrics

Earnings

Revenue, Q3 2026₩119.8bn As of Sep 30, 2026 Source 1 ↗
Revenue QoQ+73.9% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Revenue YoY+144.4% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income, Q3 2026₩78.9bn As of Sep 30, 2026 Source 1 ↗
Operating income QoQ+130.8% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income YoY+195.8% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗

Share buybacks

Buyback decided, last 3 months₩0 As of Nov 19, 2026
Buyback decided, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 3 months₩0 As of Nov 19, 2026
Shares acquired, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 3 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 3 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Buyback decided, last 12 months₩0 As of Nov 19, 2026
Buyback decided, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 12 months₩0 As of Nov 19, 2026
Shares acquired, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 12 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 12 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗

Potential dilution

CB/BW/EB issued, last 12 months₩0 As of Nov 19, 2026
Rights offering new shares, last 12 months731,078 shares As of Oct 6, 2026 Source 1, Source 2, Source 3, Source 4
Potential new shares, last 12 months731,078 shares As of Oct 6, 2026 Source 1, Source 2, Source 3, Source 4
Potential new shares, % of shares1.4% As of Oct 6, 2026 Source 1, Source 2, Source 3, Source 4, Source 5 ↗
Conversion price adjustments, last 12 months0 As of Nov 19, 2026

Supply contracts

Supply contracts, last 12 months₩0 As of Nov 19, 2026
Supply contracts vs prior-year revenue0.0% As of Nov 19, 2026
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Disclosure activity

DART filings, last 3 months14 As of Nov 19, 2026
DART filings, previous 3 months17 As of Nov 19, 2026

Insider transactions

Open-market buys, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market buys, last 12 months (amount)₩0 As of Nov 19, 2026
Open-market sells, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market sells, last 12 months (amount)₩0 As of Nov 19, 2026
Net open-market buying, last 12 months (shares)0 shares As of Nov 19, 2026
Insiders who bought, last 12 months0 As of Nov 19, 2026

Insider transactions (last 12 months)

Open-market buys: 0 shares (₩0). Open-market sells: 0 shares (₩0). Net open-market buying: 0 shares. Insiders who bought: 0.

Trade dateInsider (role)TypeSharesPriceAmount
Nov 10, 2026Kim Hang-yeon (Registered director)Other (Stock option exercise)+3,900 shares——
Aug 6, 2026Park Sun-jae (Registered director, 10%+ shareholder)Other (Bonus shares)+3,061,800 shares——
Aug 6, 2026Jeon Tae-yeon (Registered director)Other (Bonus shares)+2,160 shares——
Aug 6, 2026Kim Hang-yeon (Registered director)Other (New report)+3,000 shares——
Aug 6, 2026Kim Hang-yeon (Registered director)Other (Bonus shares)+900 shares——
Aug 6, 2026Ko In-yeong (Registered director)Other (Bonus shares)+15 shares——

Annual financials

YearRevenueOperating income
2025₩215.9bn₩106.9bn
2024₩102.9bn₩25.4bn
2023₩96.5bn-₩9.7bn

Filing timeline